Maggie L. Shaw

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences clinical outcomes in this population.

The authors of this study evaluated outcomes among children aged 7 to 16 years, all living with type 1 diabetes (T1D), who attended a 3-day virtual education camp that focused on their use of a closed-loop control (CLC) system for insulin delivery.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, discusses the important need for chronic cough therapies and what issues with current treatments should be addressed by next-generation medications.

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan.

Continuous glucose monitor (CGM) use as part of a telemedicine program in patients with type 2 diabetes transitioning out of a hospital setting and to a different diabetes therapy was evaluated in this new open-label study.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses the medicines discovery process and how real-world data can be used to evaluate patient and tumor response to treatment regimens.

Anna Brewster, services and volunteer manager at The Food Chain, a London-based charity that provides short-term assistance to persons living with HIV (PLWH), discusses how education provided through the Eating Positively program connects the importance of food and proper nutrition to health outcomes.

Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.

Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, delves into how real-world data and evidence generation have changed, both within the past year and since the beginning of the COVID-19 pandemic.

Infertility as a predisposing factor for heart failure (HF) was the subject of this new study evaluating outcomes among postmenopausal women.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.

This new study among a patient population living with type 1 diabetes compared their outcomes according to their type of insulin pump therapy: sensor-augmented pump, predictive low-glucose suspend, and hybrid closed-loop (HCL).

A new study incorporated use of readings from continuous glucose monitors (CGMs) to establish reference sensor glucose ranges among healthy nondiabetic children aged 1 to 6 years.

In this study, investigators from Pennsylvania and New York evaluated outcomes among patients following their hospitalization for heart failure (HF) who did or did not participate in a remote monitoring program that included financial incentives for adherence.

Anna Marzec-Bogusławska, MD, MPH, managing director, National AIDS Center, Warsaw, Poland, discusses how stigma and discrimination permeated the beginning of the HIV/AIDS epidemic the country in the early 1980s and ways that advocates stepped up to overcome peoples’ fears.

In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital discharge after they survived acute onset of HFrEF.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the placebo effect seen in clinical trials of chronic cough treatment.

This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Using socioeconomic status (SES) as their primary exposure, investigators from McGill University, University of Manitoba, Institut National de Santé Publique du Québec, and Laval University investigated reasons behind insulin pump uptake disparities in the Canadian provinces of Manitoba and Québec.

These investigators wanted to better understand the reasons for the increased risk for acute myocardial infarctions among young women, who have the largest increase in hospitalization for heart attacks.

Nicoleta Dascalu, founding member and advocacy manager of Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS), discusses the status of care for persons living with HIV/AIDS (PLWH) in Romania, including health care coverage and lack of adequate medication access.

Investigators from Malaysia utilized data from real-time continuous glucose monitoring (CGM) among study participants who were considered overweight or obese to evaluate their risk of type 2 diabetes (T2D) associated with a rice-based meal and its impact on postprandial hyperglycemia.

Jason Myers, PhD, CEO of the New Zealand AIDS Foundation, addresses how New Zealand promptly adjusted its delivery of services for people living with HIV and AIDS in New Zealand, with examples including HIV self-test kits, online counseling, and provision of mental health care assistance.

This systematic review and meta-analysis used a literature search to gather data from long-term randomized controlled trials on the effectiveness of closed-loop insulin systems (CLS) among nonpregnant patients with type 1 diabetes (T1D).

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, prompted by growing interest in its use as a predictive biomarker for HF.

There may be a small, but not overwhelming, benefit for certain individuals aged 40 to 59 years who have a slightly elevated risk of future cardiovascular disease (CVD) to start taking aspirin, according to an update released by the US Preventive Services Task Force (USPSTF).

This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion (CSII) or a basal-bolus regimen.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.